References
- Grasselli G, Pesenti A, Cecconi M: Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323: 1545–1546.
- Fleming TR, Nason M, Krause PR, Longini IM, Henao-Restrepo AM: COVID-19 vaccine trials: the potential for „hybrid” analyses. Clin Trials 2021; 18: 391–397.
- Gringeri M, Mosini G, Battini V, Cammarata G, Guarnieri G, Carnovale C et al.: Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility. Hum Vaccin Immunother 2021; 17: 2969–2971.
- Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M et al.: BNT162b2 vaccine induces neutralizing antibodies and polyspecific T cells in humans. Nature 2021; 595: 572–577.
- Skowronski DM, De Serres G: Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2021; 384: 1576–1577.
- Cohen D, Hazut Krauthammer S, Cohen YC, Perry C, Avivi I, Herishanu Y et al.: Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur J Nucl Med Mol Imaging 2021; 48: 3540–3549.
- Cohen D, Krauthammer SH, Wolf I, Even-Sapir E: Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18 F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging 2021; 48: 1854–1863.
- Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Shams J et al.: Covid-19 mRNA vaccination: age and immune status and its association with axillary lymph node PET/CT uptake. J Nucl Med 2021.
- Hiller N, Goldberg SN, Cohen-Cymberknoh M, Vainstein V, Simanovsky N: Lymphadenopathy associated with the COVID-19 vaccine. Cureus 2021; 13: e13524.
- Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M: Lymphadenopathy following COVID-19 vaccination: imaging findings review. Acad Radiol 2021; 28: 058–1071.
- Tu W, Gierada DS, Joe BN: COVID-19 vaccination-related lymphadenopathy: what to be aware if. Radiol Imaging Cancer 2021; 3: e210038.
- Vourtsis A, Berg WA: Breast density implications and supplemental screening. Eur Radiol 2019; 29: 1762–1777.
- Tagliafico AS, Mariscotti G, Valdora F, Durando M, Nori J, La Forgia D et al.: A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2). Eur J Cancer 2018; 104: 39–46.
- Tagliafico AS, Valdora F, Mariscotti G, Durando M, Nori J, La Forgia D et al.: An exploratory radiomics analysis on digital breast tomosynthesis in women with mammographically negative dense breasts. Breast 2018; 40: 92–96.
- Dialani V, James DF, Slanetz PJ: A practical approach to imaging the axilla. Insights Imaging 2015; 6: 217–229.
- Maxwell F, de Margerie Mellon C, Bricout M, Cauderlier E, Chapelier M, Albiter M et al.: Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagn Interv Imaging 2015; 96: 1089–1101.
- Patel T, Given-Wilson RM, Thomas V: The clinical importance of axillary lymphadenopathy detected on screening mammography: revisited. Clinical radiology. 2005; 60: 64–71.
- Özütemiz C, Krystosek LA, Church AL, Chauhan A, Ellermann JM, Domingo-Musibay E et al.: Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients. Radiology 2021; 300: E296–E300.
- Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN et al.: Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology Scientific Expert Panel. Radiology 2021; 300: E323–E327.